CRISIL Ratings, as the monitoring agency, has issued a report on the utilization of IPO proceeds by Akums Drugs and Pharmaceuticals for the quarter ended September 30, 2025. The report confirms that the IPO proceeds were utilized as per the disclosures made in the offer document. All government and statutory approvals for the object(s) have been obtained, and there are no major deviations observed. The gross proceeds from the IPO were ₹6,800.00 million.
CRISIL’s Monitoring Findings
CRISIL Ratings Limited has completed its monitoring of the IPO proceeds utilized by Akums Drugs and Pharmaceuticals for the period ending September 30, 2025. The monitoring agency’s report indicates full compliance with the intended use of funds, as outlined in the original IPO prospectus. The initial public offering (IPO) proceeds amounted to ₹6,800.00 million.
Utilization Details
The proceeds were allocated to the following key objectives, all of which have been fully utilized:
- Repayment/prepayment of indebtedness of the Company: ₹1,599.10 million
- Repayment/prepayment of indebtedness of its Subsidiaries: ₹2,270.90 million
- Funding incremental working capital requirements: ₹550.00 million
- Pursuing inorganic growth initiatives: ₹278.70 million
- General corporate purposes: ₹1,675.00 million
As of the report date, ₹72.98 million remains in the public offer account, allocated for issue expenses.
Source: BSE